Erasca (ERAS) Fundamentals 2026 — Revenue Analysis | SniperIQ
Erasca (ERAS) is a US-listed Healthcare company in Biotechnology with a market capitalization of $6.1B, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Erasca's market cap?
Erasca (ERAS) has a market capitalization of approximately $6.1B, trading at
What is Erasca's P/E ratio?
Erasca's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 15.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Erasca?
Erasca runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Erasca pay a dividend?
Erasca does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Erasca financially healthy?
Erasca carries a debt-to-equity ratio of 0.12x and a current ratio of 9.52x, with a market beta of 0.67. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Erasca a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Erasca (ERAS) the key facts are: market cap $6.1B, 52-week range 1.33-24.28. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Erasca's full fundamentals live
Get Erasca's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.